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Abstract This report presents a general method for screen-
ing cell surface receptors using so-called micromosaic im-
munoassays. This method employs a microfluidic chip hav-
ing n (n = 11) independent flow paths to move cells over m
(m = 11) lines of surface-patterned antibodies for screening
individual cells in a parallel, combinatorial, fast and flex-
ible manner. The antibodies are patterned as 30-µm-wide
lines on a poly(dimethylsiloxane) layer used to seal the area
of the chip in which screening is being monitored. Mouse
hybridoma cells having CD44 cell surface receptors and anti-
CD44 antibodies were used to establish a proof-of-concept
for this method. Both the capture antibodies and the cells
were fluorescently labelled to allow the position of the cells
to be accurately tracked over the binding sites using an in-
verted fluorescence microscope. The chips and cells were
maintained at a constant temperature between 20 to 37◦C,
and flow velocities of the cells over the capture areas were
100–280 µm s−1, resulting in a ∼0.1–0.3 s residency time of
the cells on each of the eleven 30 × 30 µm s2 capture areas.
Binding of the cells appeared to be specific to the capture
areas, with a yield of 30% when the assay was performed at
a temperature of 37◦C and with a slow flow velocity. We sug-
gest that this proof-of-concept is broadly applicable to the
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1 Introduction
Cellular assays are used to study how chemicals,
biomolecules and factors such as electrical and mechanical
stimuli, radiation, and heat affect the viability, metabolism,
differentiation, cytoskeleton, motility, adhesion, receptor
trafficking, and apoptosis processes of cells (Rowan et al.,
2002). Cellular assays therefore are of fundamental impor-
tance in biology, medicine, pharmacology, and biotechnol-
ogy. They are used both at a fundamental research level
as well as for diagnostics. Whereas many assays focus on
changes in the morphology, activity, or colour (due to stain-
ing) of cells, several assays aim at identifying cell membrane
receptors to classify cells, detect diseases, or elucidate bio-
logical pathways (Mattanovich and Borth, 2006).
Cellular assays are also increasingly being used to test the
safety of drugs and to identify potential drugs for cellular
receptors. Cellular assays can require testing thousands of
compounds at various concentrations, using individual com-
pounds or a combination of compounds (Persidis, 1998).
Clearly, these assays can benefit from miniaturization by de-
creasing the size and cost of the infrastructure and equipment
needed (Li et al., 2003; Prokop et al., 2004). In addition, cells
such as stem cells and cells from some mammalian cell lines
are available in very limited quantities only.
Microfluidics are emerging as a powerful class of de-
vices for performing miniaturized cellular assays (Wheeler
et al., 2003; Pihl et al., 2005; Poulsen et al., 2005), patterning
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cells (Khademhosseini et al., 2005; Chiu et al., 2000), and
controlling cellular environments (Takayama et al., 1999;
Tourovskaia et al., 2005; Li Jeon et al., 2002). These devices
can accommodate microliter and sub-microliter volumes of
samples and reagents, can provide faster time to results than
conventional technologies, can effect multiple assays in par-
allel or serial assays with high throughput, and sometimes
are portable. We have developed a class of microfluidics in
which liquids move under the action of capillary forces (De-
lamarche et al., 1997, 1998). These microfluidic chips are
autonomous and do not need pumping elements. They can
be used without peripherals for actuation. We call one in-
dependent flow path on such a microfluidic chip a capillary
system (CS) (Juncker et al., 2002). CSs can be cloned and
arrayed so as to move a number of solutions independently
and run assays in parallel. Key to using these chips is the ac-
curate patterning of receptors for analytes on the surface of a
poly(dimethylsiloxane) (PDMS) elastomer, which reversibly
seals sections of the CSs.
Assays based on this approach can be two-dimensional
and combinatorial. A first microfluidic chip with n CSs can
be used to pattern n types of capture antibodies (Abs) on
PDMS as parallel lines. A second chip having m CSs can be
used to bring m samples over the surface-immobilized cap-
ture Abs. Ligand-receptor interactions between the capture
Abs and their antigens from solution result in a maximum of
n × m binding interactions, which can be displayed as a “mi-
cromosaic” of fluorescence signals if fluorescently-tagged
detection Abs are used to reveal where antigens are captured
on PDMS (Bernard et al., 2001). Similar approaches for the
combinatorial screening of clinical analytes (Rowe et al.,
1999a,b; Kanda et al., 2004), and single-stranded DNA ana-
lytes have been developed (Nelson et al., 2001). A matrix of
surface binding interactions can also be used to detect flow-
ing antigens with a serial dilution strategy (Jiang et al., 2003).
In this paper, we explore how the concept of micromosaic
immunoassays (Bernard et al., 2001) can be applied to the
screening of cells. Several reasons motivate this work. First,
micromosaic immunoassays are efficient. One microliter of
sample or less is sufficient to screen eight or more types
of analyte. The short paths for diffusion of analytes in mi-
crochannels can greatly accelerate diffusion-limited steps.
The flow of solutions in microfluidics is typically laminar
and makes rinsing steps short and effective. A fluorescent
sandwich immunoassay having ∼10 steps can be done in
less than 10 min for detecting analytes at a concentration
level of ∼1 mg mL−1 or in ∼45 min for analytes at con-
centrations down to 1 pM (Wolf et al., 2004; Cesaro-Tadic
et al., 2004). This method suggests that cells can be screened
rapidly and using small volumes of sample. Second, using
microfluidic chips the PDMS substrate for the assay can
be patterned in a flexible manner prior to analyzing samples
(Delamarche et al., 2005). The accurate patterning of capture
Abs on a PDMS surface limits the depletion of analytes from
a small volume of sample and facilitates the reading of a large
number (up to several hundreds) of fluorescent signals. The
PDMS layer can be readily removed from the microfluidic
chip at the end of the assay and the signals analyzed using a
fluorescence scanner or microscope. With respect to cellular
assays, it should then be possible to localize the interaction
of cells with surface-bound receptors accurately. Third, the
possibility to conduct assays and calibrate them simultane-
ously using reference samples may yield a better consistency
and smaller intra-assay variation than assays do that are done
as independent experiments. Similarly, it should be possible
to screen different types of cells in parallel using a micromo-
saic format. In the remainder of this paper, we first review
how a micromosaic immunoassay for screening cells can be
set up and then provide a proof-of-concept by analyzing the
trajectories of individual cells passing in microchannels over
surface-immobilized antibodies.
2 Experimental
2.1 Chemicals and cells
Chemicals were purchased from Sigma-Aldrich or Fluka
(Buchs, Switzerland) unless otherwise stated. Cells from the
mouse hybridoma cell line PK136 were used for this work.
Briefly, these cells secrete mouse IgG2a monoclonal anti-
body, which reacts with mouse natural killer cells. These
hybridomas were obtained by fusion between SP2 myeloma
cells and spleen cells (C3H × BALB/c) immunized with
mouse spleen cells (Koo and Peppard, 1984; Kung et al.,
2001). The cells were cultured and prepared using phosphate-
buffered saline with pH 7.4 (PBS), bovine serum albumin
(BSA), Tween 20, fluorescein diacetate, dimethylsulfoxide
(DMSO), Iscove’s Modified Dulbecco’s Medium (Gibco,
Invitrogen, Switzerland), foetal calf serum, normal mouse
serum, hyaluronidase, and propidium iodine. The cells were
cultured with 5% atmospheric CO2 at 37◦C in Iscove’s Mod-
ified Dulbecco’s Medium, which was supplemented with
10% foetal calf serum, in a cell incubator.
Anti-CD44 monoclonal antibodies (BD Biosciences, San
Jose, CA), either conjugated with FITC or Phycoerythrin,
were used as capture antibodies for the microfluidic-based
assays (see below) as well as for fluorescence-activated
cell sorting (FACS). FACS (FACScan, BD Biosciences,
San Jose, CA) was used to verify the presence of CD44
on the PK136 cells before performing microfluidic-based
assays as follows. First, cells were taken from the cell
culture and washed, resuspended in PBS at a concentration
of 2.5 × 106 cells mL−1, and 200 µL of the suspension
was loaded into the wells of a 96 microtiter plate (Falcon),
which corresponds to ∼500,000 cells per well. The cell
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aliquots were centrifuged, and their Fc receptors (a potential
nonspecific cellular receptor for antibodies) blocked using
100 µL solution of mouse serum in PBS (1:50) for 15 min
at room temperature. To label the CD44 cellular receptors
fluorescently, the cells were centrifuged again and incubated
in a 1:200 solution of antibody (anti-CD44-Phycoerythrin
conjugate) in 0.1% normal mouse serum in PBS for 15 min
at room temperature. The cells were centrifuged and resus-
pended in 200 µL of PBS twice. Immediately prior to FACS,
propidium iodine was added to sort out nonviable (necrotic)
cells. Viable cells were assessed using FACS scatter plots
by gating on propidium iodine-negative populations.
Cells for the microfluidic-based assays were handled and
stained as follows. A suspension of PK136 mouse hybridoma
cells was taken from the cell culture and incubated for 1 h
at 37◦C with hyaluronidase (5000 IU per ∼5 × 106 cells
mL−1) to prevent hyaluronic acid-mediated cell aggregation
(Miyake et al., 1990). To visualize the cells during the assays,
0.1 µL of a 5 mg mL−1 solution of fluorescein diacetate in
DMSO was added to 1 mL of cell suspension. After 30 min of
incubation at room temperature, the cells were washed three
times with PBS, resuspended in a 2% solution of normal
mouse serum in PBS, and used after a minimum resting time
of 15 min.
2.2 PDMS and microfluidic chips
The prepolymers of PDMS (Sylgard-184, Dow Corning,
Midland, MI) were mixed at a 10:1 ratio using a Dopag
Mixer (Cham, Switzerland), dispensed on the bottom of a
Falcon Petri dish, and cured for at least 24 h at 60◦C. PDMS
slabs of desired dimensions were then cut and used to pre-
pare lines of capture Abs or simply to seal some areas of the
chips during the assays.
The microfluidic chips were microfabricated using
photolithography. A chrome mask was used to pattern a
photoresist on 4” silicon wafers and to etch selectively 20 µm
of silicon using a deep reactive ion etcher (STS ICP, Surface
Technology Systems plc, Newport, U.K.). After removal of
the photoresist, the wafers were coated with Ti (10 nm) and
Au (150 nm), and then diced to yield individual chips. Each
microfluidic chip had 11 independent CSs (Cesaro-Tadic
et al., 2004). The top surface of each chip was microcontact-
printed with octadecanethiol to form a hydrophobic coating
(advancing contact angle with water of ∼115◦). The
chips were then immersed in a 10 mM ethanolic solution
of thiolated poly(ethylene glycol) (ABCR, Karlsruhe,
Germany) for 30 s to make the recessed areas of the chips
wettable (advancing contact angle with water of ∼40◦) and
protein-repellent. Used chips were cleaned prior to reuse by
immersion in a “Piranha” solution (H2SO4:H2O2, 3:1, CAU-
TION) (Comment), after which the chips were copiously
rinsed with deionised water and dried under a stream of N2.
3 Patterning of capture antibodies and screening assays
Capture Abs were patterned on PDMS by covering the mi-
crochannels of a chip with a ∼1-mm-thick slab of PDMS and
filling the loading pads of the chip with 0.5 µL of a 0.1 mg
mL−1 PBS solution of anti-CD44 Ab conjugated with FITC.
After 2 min, most of the Ab aliquots had passed through the
microchannels, which were flushed by adding (i) 0.5 µL of
a 1% solution of BSA in PBS and (ii) 0.5 µL of PBS to the
loading pads. Finally, the PDMS layer was removed manu-
ally from the chip, rinsed with deionised water and blown
dry under a stream of N2.
Next the PDMS layer was brought into contact with a
second microfluidic chip so as to expose the lines of capture
Abs orthogonally to the microchannels of the second chip.
A slab of PDMS was used to seal the capillary pumps . The
chip was then placed on a thermally conductive adhesive,
which covered a thermoelectric element. The cellular assays
proceeded by filling the loading pads of the chip with 0.5 µL
of a 1% BSA solution in PBS and 0.5 µL of a 107 cells mL−1
suspension of PK136 hybridomas. During the filling of the
capillary pumps, air trapped in the pumps slowly diffused
through PDMS, which resulted in a slow and homogenous
flow rate of solution in all microchannels. After dispensing
the cells, two cover glass slides separated by a 1-mm-thick
PDMS frame were quickly placed over the chip and its ther-
moelectric element. The thermoelectric support with the chip
and glass slides were turned upside down and placed on the
stage of an inverted fluorescence microscope (Axiovert 100,
Zeiss, Switzerland). A thermo-regulator (TC2812, Minco,
Niederuzwil, Switzerland) with pulse-width modulation and
thermo sensor was used to regulate the temperature of the
thermoelectric element and chip from 20 to 37◦C. A digital
camera (Coolpix E990, Nikon) was used to record the tra-
jectory of cells flowing over the region in which the capture
Abs are located. The focal plane of the microscope was set to
the lines of capture Abs. The videos showing the trajectories
of the cells were analyzed after the assay using the software
Image Pro and its object-tracking functions.
4 Results and discussion
The influence of the environmental parameters (e.g. culture
medium, pH, temperature, shear stress) on the metabolism of
living cells and the tendency of cells to sediment require the
adaptation of micromosaic immunoassays to the particular
needs of living cells. The setup used for screening cells using
CSs is displayed in Fig. 1. It consists of a microfluidic chip of
silicon, covered with a thin layer of Au and self-assembled
monolayers, and has two separate blocks of PDMS. One
block serves as the substrate for the assay: it is patterned with
lines of capture Abs and placed on the region in which the
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Fig. 1 Experimental setup for a micromosaic immunoassay screening
of cells. Aliquots of cell suspensions are placed in the loading pads of
independent capillary systems, from where they fill the microchannels
and capillary pumps of the capillary systems. As the cells cross lines
of capture Abs, which are patterned on a sealing PDMS layer, capture
of some cells may occur. A heater, two glass slides, and conductive
foil spacers form a chamber inside which the microfluidic chip and the
cells are maintained at a constant temperature; moreover evaporation of
water from the loading pads is negligible. The trajectory of the cells in
the region of the capture sites is monitored in the X - and Y -directions
using an inverted fluorescence microscope and recorded as a video for
analysis. The fluorescence microscope images show (left) three lines
of capture Abs (orange) and a cell (green) moving in one microchannel
and (right) ∼300 nL of cell suspension in one loading pad
microchannels of the CSs run parallel. The second PDMS
block covers the capillary pumps of the CSs. It helps to
maintain a reproducibly low flow rate in the microchannels
when the solutions added to the loading pads progressively
displace air from the CS and fill the capillary pumps. To
prevent cell lyses due to fast cell flow in the microchannels,
a small volume of buffer is added first to each loading pad so
as to fill the microchannels up to approximately the inlet of
the capillary pumps. During the assay, the air compressed by
the filling liquid permeates through the PDMS, resulting in a
slow flow of solution inside the microchannels. The microflu-
idic chip is placed on a heat-conductive adhesive and heating
device. Once the solutions with cells are loaded on the chip,
the chip and its heating element are placed upside down on
the stage of an inverted fluorescence microscope. Two glass
slides separated by ∼1-mm-thick slabs of PDMS insulate
the chip from the microscope stage to prevent condensation
of water in front of the microscope’s optical path. The chip
was maintained at a constant temperature between 20 and
37◦C for the assays. Sedimentation of cells resulted in cells
coming into contact with the capture sites. The fluorescence
images in Fig. 1 show cells labelled with fluorescein (green)
and capture sites on PDMS having antibodies labelled with
R-phycoerythrin (orange).
For the proof-of-concept shown here, we selected mouse
hybridoma cells having a CD44 cell surface receptor. These
cells partly derive from white blood cells, and CD44 is in-
volved in numerous cell-cell interactions important for lym-
phocyte activation, hematopoiesis, and tumour metastasis. In
addition, the transmigration of blood vessel walls by white
blood cells is a physiological process, which is mediated by
rolling and tethering through receptor molecules in the cell
membranes (Chen et al., 1997; Eniola et al., 2003). This
cell-binding mechanism guides immunocompetent cells to
inflammatory target areas. The receptor profile expressed
and displayed by the endothelial cells provides specificity
for subpopulations of white blood cells that can be differ-
entiated by their membrane protein expression, that is their
cluster of differentiation (CD) (Chen et al., 1997). Using a
micromosaic immunoassay and specific antibodies, it should
be possible to imitate the capture of a subpopulation of white
blood cells on the surface of blood vessels to a certain ex-
tent: depending on the combination of antibody and receptor,
rolling, tethering or firm binding of leukocytes to a surface
may occur under a certain shear rate. In clinical medicine,
the examination of white blood cell subpopulations is crucial
for diagnosis and treatment of diseases, e.g. AIDS. A device
capable of separating subpopulations would allow further
examination of these cells or an isolated ex vivo treatment of
these cells and their reinsertion into the blood stream. In cur-
rent clinical practice, conventional FACS machines require
incubating the cell sample to be examined with fluorescently
labelled antibodies for at least half an hour.
The cellular assays consist in following the real-time tra-
jectories of the cells in each microchannel along the main axis
of the microchannel (X -coordinate) and orthogonal to the mi-
crochannel (Y -coordinate). Figure 2 shows the trajectory of
cells in 11 independent microchannels with the microfluidic
chip maintained at 20◦C. First, ∼140 cells are tracked during
42 s and their Y -positions are analyzed, Fig. 2(a). Short seg-
ments in this graph correspond to cells entering and leaving
the channels without noticeable interaction with the capture
Abs. On average, the cells remain ∼2.5 s in the length of the
microchannels that is visible in the field of view and their
mean velocity in the microchannel is ∼280 µm s−1. Note
that the curvature of the segments reflects an optical artifact
and not a curved trajectory of the cells in the microchannels.
In addition, several cells bind to the capture areas and be-
come immobile during this experiment. The graph in Fig.
2(b) shows the trajectory of selected cells along the main
axis of the microchannels as a function of time. Cells flow
along the microchannels at a steady speed until they become
bound to one of the 11 capture zones they cross.
Figure 3 shows selected frames of a video in which the
trajectory of cells over the capture areas was followed. This
Springer
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Fig. 2 Trajectories of PK136 hybridoma cells having CD44 surface
receptors and flowing inside microchannels across patterned lines of
anti-CD44 Abs. (a) Graph showing the lateral positions of the cells
inside the microchannels as a function of time. The entrance and exit
coordinates of one cell flowing through a microchannel without binding
are marked. Following a binding event, cells acquire an invariant Y -
coordinate. (b) Graph showing the longitudinal position of cells along
the microchannels as a function of time. Cells flow over 11 areas having
capture Abs. The trajectories of only a few binding cells are depicted
for better clarity
experiment was done at 37◦C to optimize the chances of
binding of the cells. The fluorescently-labeled capture Abs
appear faint as a result of photobleaching, whereas cells ap-
pear as bright green ∼10–15 µm-wide spheres. The frames
cover a timeframe of ∼20 s during which the cells flowed
with an average velocity of 150 ± 45 µm s−1 or equiva-
lent flow rate of ∼0.15 nL s−1. This range of velocities
is mainly due to the laminar flow profile, which transports
cells positioned in the center of the microchannel faster than
those positioned elsewhere. The average residence time of
one cell above one 30 × 30 µm2 capture area is 0.2 s. A
basic analysis of the trajectories and binding of the cells us-
ing commercial vision software revealed that ∼30% of the
cells were captured on one of the 11 capture sites aligned
Fig. 3 Outline (a) and movie frames (b–h) illustrating a micromosaic
immunoassay with cells as recorded using a fluorescence microscope
and video camera. The cells are PK136 hybridomas, have CD44 surface
receptors, and are labelled with a fluorescein dye (green). Anti-CD44
Abs labelled with fluorescein, which are patterned as lines on a PDMS
layer used to seal the microchannels, form the capture areas. The cells
flow from left to right inside 30-µm-wide microchannels. The cells
binding to anti-CD44 Abs are circled. The video corresponding to this
assay is provided as supplementary material
in each microchannel. A more detailed analysis would re-
quire the identification of the three-dimensional position of
the cells in the microchannels and the calculation of the spe-
cific velocity and residence time on the capture areas for
each cell. Such an analysis could for instance use methods
known from particle image velocimetry, which requires a
high-speed imaging setup. Interestingly, the retardation of
some cells passing over surface-immobilized receptors can
yield insight into the protein expression of retarded cells
(Fitzpatrick et al., 2006). This suggests that qualitative cel-
lular assays can provide useful information without the need
for full parameterization of the factors governing the inter-
action between the cells and the receptors.
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The flow rate of the cell suspension may be varied us-
ing peripheral equipment having several heating/cooling el-
ements placed in contact with the microfluidic chip (Zimmer-
mann et al., 2005) to study the effect of hydrodynamic forces
on the behavior of immobilized cells (Gallant et al., 2002).
The direction of flow, for example, can be changed back and
forth to obtain statistical information on the binding of one
cell over one type of capture area. In addition, micromosaic
immunoassays for screening cell surface receptors can be
combined with an interrogation of the mechanical properties
of cells (size and elasticity) to identify particular cells, such
as cells that are infected with parasites (Shelby et al., 2003).
5 Conclusions
The proof-of-concept shown here can be further refined.
First, many types of capture Abs may be used to screen for
various types of cells or receptors simultaneously. This may
require using cells that are labeled differently in a first step
when developing the assay. Second, the geometries of the mi-
crochannels and capture sites can be varied to capture cells at
particular locations. This could minimize or prevent the risk
of collisions and interferences between flowing and surface-
immobilized cells. Third, “advanced” capillary pumps can
be designed (Zimmermann et al., 2006) so as to vary the flow
conditions in the microchannels and to study the influence
of the flow rate on the statistics of binding. In this paper, the
emphasis was to miniaturize the assays and screen individual
cells from microliter volumes of samples. Larger volumes of
sample can of course also be used, and capture sites can be
made much larger and continuous, for example. The setup,
microscope, camera and chemicals used here are relatively
standard and did not require any particular modification for
the assays, except for holding the microfluidic chips on an
element having a controlled temperature.
We believe that the work shown here is broadly applica-
ble and provides a flexible and efficient method for screening
cell surface receptors. This concept may be used for histo-
compatibility testing to screen human leukocyte antigens.
It can also be used for blood typing and for verifying the
presence of cells in routine applications in which samples
are available in limited volumes. There is a number of diag-
nostics that require the analysis of the number and type of
white blood cells, and the status of some diseases such as
HIV can be monitored by counting CD4-T-cells, for exam-
ple. Although we are mainly interested in developing simple
research and diagnostic platforms based on capillary-driven
microfluidics, actuation mechanisms may be added to the mi-
crofluidic chips used here for sorting cells (Fu et al., 1999;
Huh et al., 2005). In general, multidimensional assays are
needed when testing large numbers of cells and compounds
to obtain statistically meaningful results. It is therefore de-
sirable to have cell assays that can screen cell/compound in-
teraction in parallel (i.e. multiplexed assays), a task at which
micromosaic assays excel.
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